Role of nebulized amphotericin b in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature

Rosaria Casciaro, Aldo Naselli, Federico Cresta, Mirco Ros, Elio Castagnola, Laura Minicucci

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To review the data available in literature about nebulized amphotericin B (AMB) in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) and to report our experience in the use of this drug, with a particular therapeutic scheme.  Case Report: We used nebulized liposomal amphotericin B (L-AMB) in a patient affected by CF, complicated by ABPA. The previous combined treatment with oral steroids and azoles had no respiratory benefit and caused relevant side effects. Amphotericin B has always been well tolerated and permitted a slight steroid tapering. We also observed benefits in pulmonary function and laboratory tests. Conclusions: Few data are available in literature about the use of nebulized AMB in CF and there are no RCTs evaluating antifungals in CF-ABPA. In our opinion, the reported case suggests that nebulized L-AMB could represent a possible strategy in ABPA management in CF patients.

Original languageEnglish
Pages (from-to)307-311
Number of pages5
JournalJournal of Chemotherapy
Volume27
Issue number5
DOIs
Publication statusPublished - Oct 1 2015

Keywords

  • Amphotericin B
  • Antifungal therapy
  • Aspergillosis
  • Azole antifungals
  • Cystic fibrosis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Role of nebulized amphotericin b in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature'. Together they form a unique fingerprint.

Cite this